Abbott Laboratories stock: EUR 98.25, up 1.14% premarket
Published on 11/03/2026 at 08:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points for investors
- Abbott focuses on life-changing healthcare technology across its business.
- The company remains a US-listed healthcare name with a broad technology-driven positioning.
- Investors can follow further company developments and market context ahead of the Xetra session.
Abbott Laboratories stock traded at EUR 98.25 on Lang & Schwarz at 08:25 CET on Tuesday, November 3, 2026, 1.14 percent above the Xetra close of Monday, November 2, at EUR 97.14.
Healthcare technology remains the focus
Abbott's website describes the company's focus as life-changing healthcare technology. Its public positioning spans products and services intended to support healthcare applications, giving investors a concise view of the group's operating profile. The company presents that focus through its official website.
The premarket indication places the stock above the latest completed Xetra session. For investors, the next trading phase will show whether the European listing maintains that level when regular liquidity returns. The move should be read as a market indication rather than as a confirmed opening price.
Abbott Laboratories stock remains tied to developments in medical technology, diagnostics and healthcare products. Those areas can expose the company to changing demand, product execution and regulatory considerations, while also giving the business several operating drivers.
US-listed healthcare shares remain the relevant market context for Abbott Laboratories stock; investors can follow the S&P 500 for broader market orientation.
Further developments are available in the more news and analyses on Abbott Laboratories stock. Investors can also use the real-time quote of Abbott Laboratories stock for ongoing market monitoring.
